Current $266, DCF FV $357 = 34% upside, P(above)=84.3%. Thesis: 7.2% revenue growth, PAMA freeze (2026) + caps (2027-29) remove headline risk, CDx/specialty diagnostics are structural growth engines. Prior $285 target was too conservative — DCF FV is $357. Raising implied target to $320-330. Missing element: no near-term catalyst to close the gap to FV; dividend growth supports but doesnt accelerate re-rating.
Fair Value Distribution — percentile bands
84.7% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
-0.4%/yr
±5.1% · revenue growth to justify current price
FCF-Based Reverse DCF
11.3%/yr
±3.0% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
FY2025 strong results: 7.2% revenue growth, 4.4% organic, both segments expanding margins. Margin expansion driven by operational leverage and mix improvement (specialty/CDx growth). Strategic positio...